Ivan B.
- Country
- France
- Department
- Medecine Interne DIAGORA
Research Overview
- Evaluation of Etavopivat, a Pyruvate Kinase Activator, in a Randomized, Placebo-Controlled Study for Sickle Cell Disease in Patients Aged 12 to 65 Years
- A Phase IB, Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso‑Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)
- A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD)
Data & Insights
Has run more than one trial at 5 of 27 partner sites.
Specializations
Hematological Disorders
The investigator specializes in treating sickle cell disease (SCD), with particular emphasis on managing vaso-occlusive episodes (VOE) and related complications.
- Acute VOE Management
- Prevention of Vaso-occlusive Episodes
- Hemoglobin Improvement Strategies
Their research encompasses novel therapeutic approaches for SCD patients aged 12 to 65 years.
Therapeutic Development
Focus on evaluating novel treatments including crovalimab and etavopivat for sickle cell disease management.
- Drug Safety Assessment
- Pharmacokinetic Studies
- Pharmacodynamic Evaluation
The investigator examines both preventive and acute treatment modalities for SCD complications.
Clinical Outcomes
Expertise in measuring treatment efficacy through multiple clinical endpoints in sickle cell disease.
- Hemoglobin Level Assessment
- VOC Rate Analysis
- Treatment Response Monitoring
Their work focuses on evaluating therapeutic interventions in multicenter clinical settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.